ASX Growth Stocks With High Insider Ownership

Simply Wall St.
昨天

The Australian market has recently shown positive momentum, with the ASX200 closing up 0.92% at 8,070 points, driven by strong performances in sectors like Energy and Utilities. In this environment of growth and sectoral strength, identifying stocks with high insider ownership can be particularly appealing as it often suggests confidence from those who know the company best.

Top 10 Growth Companies With High Insider Ownership In Australia

Name Insider Ownership Earnings Growth
Alfabs Australia (ASX:AAL) 10.8% 41.3%
Fenix Resources (ASX:FEX) 21.1% 47.8%
Cyclopharm (ASX:CYC) 11.3% 97.8%
Acrux (ASX:ACR) 15.5% 106.9%
Newfield Resources (ASX:NWF) 31.5% 72.1%
Echo IQ (ASX:EIQ) 19.8% 87.1%
Titomic (ASX:TTT) 11.2% 77.2%
Plenti Group (ASX:PLT) 12.7% 85%
Image Resources (ASX:IMA) 16.1% 127.3%
BETR Entertainment (ASX:BBT) 38.6% 77.5%

Click here to see the full list of 96 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Let's dive into some prime choices out of the screener.

Develop Global

Simply Wall St Growth Rating: ★★★★★★

Overview: Develop Global Limited, with a market cap of A$837.02 million, is involved in the exploration and development of mineral resource properties in Australia through its subsidiaries.

Operations: The company generates revenue primarily from its Mining Services segment, which accounts for A$194.45 million.

Insider Ownership: 20.8%

Revenue Growth Forecast: 47.5% p.a.

Develop Global's recent earnings report showed significant revenue growth to A$113.02 million, up from A$65.8 million a year ago, and a shift from a net loss to a net income of A$0.94 million. Despite limited insider trading activity recently, the company is forecast to grow its revenue at 47.5% annually, outpacing the market average of 5.6%. It trades at good value compared to peers and is expected to achieve profitability within three years with high return on equity projections.

  • Unlock comprehensive insights into our analysis of Develop Global stock in this growth report.
  • In light of our recent valuation report, it seems possible that Develop Global is trading behind its estimated value.
ASX:DVP Ownership Breakdown as at Apr 2025

Guzman y Gomez

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Guzman y Gomez Limited operates and franchises quick service restaurants across Australia, Singapore, Japan, and the United States with a market cap of A$3.37 billion.

Operations: The company's revenue segment primarily consists of its restaurant operations, generating A$413.26 million.

Insider Ownership: 14.1%

Revenue Growth Forecast: 18.4% p.a.

Guzman y Gomez Limited's recent sales figures show strong growth, with Q1 2025 network sales reaching A$289.5 million, up from A$234.2 million the previous year. The company has transitioned to profitability, reporting a net income of A$7.3 million for H1 2024-25 compared to a loss previously. Despite substantial insider selling over the past three months, revenue is forecasted to grow at 18.4% annually, surpassing market averages and contributing to expected profitability within three years.

  • Click to explore a detailed breakdown of our findings in Guzman y Gomez's earnings growth report.
  • Our expertly prepared valuation report Guzman y Gomez implies its share price may be too high.
ASX:GYG Ownership Breakdown as at Apr 2025

PYC Therapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: PYC Therapeutics Limited is an Australian drug-development company focused on discovering and developing novel RNA therapeutics for treating genetic diseases, with a market capitalization of A$658.38 million.

Operations: The company's revenue segment includes A$24.99 million from the discovery and development of RNA therapeutics targeting genetic diseases.

Insider Ownership: 38%

Revenue Growth Forecast: 25% p.a.

PYC Therapeutics is trading significantly below its estimated fair value and forecasts suggest robust growth, with earnings expected to rise 29.69% annually. The company anticipates profitability within three years, outpacing market averages. Recent developments include a completed A$145.82 million equity offering and progress in clinical trials for PYC-003, indicating potential future revenue streams despite current net losses of A$25.57 million for H2 2024 compared to last year’s figures.

  • Delve into the full analysis future growth report here for a deeper understanding of PYC Therapeutics.
  • Our valuation report unveils the possibility PYC Therapeutics' shares may be trading at a premium.
ASX:PYC Ownership Breakdown as at Apr 2025

Next Steps

  • Navigate through the entire inventory of 96 Fast Growing ASX Companies With High Insider Ownership here.
  • Contemplating Other Strategies? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include ASX:DVP ASX:GYG and ASX:PYC.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10